When to treat, when to reassure, when to refer REVIEW s ABSTRACT Many women have breast symptoms-swelling and tenderness, nodularity, pain, palpable lumps, nipple discharge, or breast infections and inflammation. Fortunately, relatively few have breast cancer. Physicians must distinguish benign breast conditions from malignant ones, and know when to refer the patient to a specialist. We have included some of the newer diagnostic techniques and the approach to patients with nonpalpable lesions detected on a screening mammogram.
ANY WOMEN HAVE SYMPTOMS of breast disease, but few have cancer. Yet these symptoms are understandably a source of great concern for women.
The challenge for physicians is to distinguish between benign and malignant lesions, and to know when prompt referral to a surgeon or other specialist is necessary.
Making such discriminations is not easy, as the conditions are diverse and vary in presentation. They include:
• Physiologic swelling and tenderness • Nodularity • Breast pain • Palpable breast lumps • Nipple discharge • Breast infections and inflammation.
This article presents an approach to benign breast conditions for the primary care physician, including their diagnosis, management, and appropriate referral. A systematic approach and a careful history and physical examination will simplify this seemingly complicated group of disorders.
s SYMPTOMS COMMON, BUT RARELY MALIGNANT
The incidence of benign breast disease is difficult to assess clinically. 1 A retrospective cohort study in a health maintenance organization found that 16% of women 40 to 70 years of age presented with breast symptoms, 2 but only 6% of those with symptoms had breast cancer.
In another study in Sheffield, UK, 60% of women referred to surgical outpatient or out-reach clinics because of breast symptoms were diagnosed with benign breast disease. 3 
s TWO CLASSIFICATION SYSTEMS
Formerly, the term "fibrocystic disease" was used to describe all benign breast conditions. However, this term caused confusion in distinguishing between normal physiologic changes and pathologic ones. 4 Currently, two classification systems are in use: pathologic and clinical.
Pathologic classification
The pathologic classification (TABLE 1), based on findings on biopsy, is useful in assessing the risk of breast cancer in women with benign breast disease. Most benign breast lesions are not associated with an increased risk of breast cancer.
Nonproliferative disease accounted for 70% of cases of benign breast lesions in a series of more than 10,000 consecutive breast biopsies performed in three hospitals in Nashville, Tenn. 5 It is not associated with an increased risk of breast cancer.
Proliferative disease without atypical hyperplasia accounted for 27% of the cases in the Nashville series. Unless the patient has a family history of breast cancer, proliferative disease without atypical hyperplasia increases the risk of breast cancer only slightly: the relative risk in the Nashville series was 1.3 without a family history and 2.4 with a family history.
Atypical hyperplasia accounted for 4% of cases in the Nashville series. It is associated with a fourfold to fivefold increase in the risk of breast cancer, and a family history in the presence of atypical hyperplasia boosts the risk of breast cancer even more. 6 
Clinical classification
The clinical classification of benign breast disease (TABLE 2) is based on signs and symptoms and is more useful for the primary care physician. The rest of this paper is based on the clinical classification.
s PHYSIOLOGIC SWELLING AND TENDERNESS
Most women in their reproductive years experience varying degrees of breast swelling, fullness, or tenderness. These changes occur premenstrually and are cyclic, physiologic, and hormonally mediated. 7, 8 Physical examination reveals nodularity, lumpiness, or tenderness.
If in doubt about the nature of the lumpiness, ask the patient to return after one or two menstrual cycles during midcycle when these changes regress. 9 At this point, both tenderness and lumpiness should be significantly diminished. 
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Patients with these physiologic changes should be reassured. Treatment, if needed, consists of analgesics and a well-fitting brassiere. 8 
s NODULARITY
Nodularity is also a physiologic, hormonally mediated change characterized by lumpiness of the breast and varying degrees of pain and tenderness. The symptoms are most prominent about 1 week before menstruation and subsequently decrease.
Physical examination may reveal an area of nodularity or thickening, poorly differentiated from the surrounding tissue and often in the upper outer quadrant of the breast. If the changes are symmetric (ie, the same in both breasts), they are rarely pathologic. 9 Follow-up of asymmetric nodularity Follow-up of asymmetric nodularity (ie, not the same in both breasts) should be scheduled at midcycle after one or two menstrual cycles. 9 If the nodularity or thickness persists, the patient should be referred to a surgeon for evaluation and undergo bilateral mammography if older than 35 years. 9 For patients younger than 35 years, an ultrasound may be helpful. However, these patients also need a surgical referral.
Treatment of nodularity
A variety of treatments have been reported for breast nodularity. Conservative measures include mild analgesics and supportive brassieres. 8 Other treatments are described in the next section on breast pain, as most of the studies evaluating the efficacy of treatment were conducted in women with both breast nodularity and pain or tenderness.
s BREAST PAIN
Breast pain, or mastalgia, is the second most common breast symptom for which women seek medical attention, 3,10 the first being a lump in the breast. Most women with breast pain do not have cancer. 11 Common symptoms associated with mastalgia are heaviness and tenderness. The discomfort is often in the upper outer quadrant, diffuse, and may radiate to the axilla or upper arm. 8, 12 Mastalgia is broadly classified as either cyclic or noncyclic, based on its relationship to the menstrual cycle. 12 Cyclic mastalgia usually starts 1 to 3 days before the onset of menses and subsides after menses are completed. It accounts for about two thirds of all cases of mastalgia and is more responsive to treatment than noncyclic mastalgia. 13 Noncyclic mastalgia is unrelated to the menstrual cycle and shows a poorer response to treatment.
Follow-up of breast pain
Any palpable mass or asymmetry on clinical breast examination should be further evaluated. Diffuse nodularity, often bilateral, is not uncommon and is a benign finding.
If the breast examination is normal, most women younger than 35 years do not need any further diagnostic evaluation, as the risk of breast cancer is low. 11, 14 On the other hand, women older than 35 years should have a mammogram even if the physical examination is normal to detect the rare presence of malignancy. 14, 15 A patient with mild pain of less than 6 months' duration who is started on conservative treatment should be followed up after 3 to 6 months unless the pain gets worse. 14 If the pain persists or is severe despite initial treatment, or if the patient has concerns, referral to a breast specialist is indicated for possible initiation of medical therapy. 15 
Treatment of breast pain
Up to 85% of patients respond to nonmedical treatment and reassurance that breast cancer is a rare cause of breast pain. Therefore, the first-line approach to all patients with mastalgia should include education and recommending the use of a well-fitting brassiere.
Dietary modifications such as caffeine reduction or avoidance, a diet low in saturated fat, and vitamin E supplementation are often recommended, even though they have not shown benefit in clinical trials. 16, 17 Nevertheless, they can't hurt.
Evening primrose oil, an herbal supplement, can be used as a first-line agent since it CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 69
427 Symmetric breast nodularity is rarely cancer has a low side-effect profile. 15 One placebocontrolled trial demonstrated a clinically significant improvement in breast pain at a dose of 1,500 mg twice daily. The drug is available in US health food stores and by prescription in the United Kingdom. 9 Various drugs have been studied for treating mastalgia and nodularity but are rarely prescribed for these conditions because of their side effects. They are mentioned for completeness:
Danazol, an antigonadotropin, has been shown in randomized studies to relieve pain in 97% of patients and to decrease premenstrual nodularity in 73% to 93%. 18 It is approved by the US Food and Drug Administration (FDA) for treating mastalgia. Common side effects include acne, weight gain, hirsutism, and menstrual dysfunction, including amenorrhea. Women in their reproductive years should use barrier contraception in view of this drug's teratogenicity and interaction with birth control pills.
Tamoxifen, a synthetic antiestrogen, relieved pain in 75% to 96% of patients in different randomized trials. 15 The drug is not approved by the FDA for treating mastalgia. Patients should be evaluated every 3 months while taking tamoxifen to monitor for irregular menstrual bleeding or menopausal symptoms. The relapse rate is as high as 39% to 48% after tamoxifen is stopped. 15 The long-term effects of tamoxifen in women of reproductive age are uncertain, and it is not considered to be a first-line drug. Tamoxifen may induce ovulation, so birth control measures need to be addressed carefully.
Bromocriptine, a dopamine receptor agonist, inhibits prolactin release. Many patients (29%) stop taking bromocriptine because of its side effects, such as headache and dizziness. 19 In addition, bromocriptine is teratogenic and can interfere with birth control pills. Its use is restricted to patients who do not respond to danazol or tamoxifen.
Hormonal agents. Estrogen-progesterone combinations have been shown to alleviate breast nodularity associated with breast pain in 70% to 90% of women. 20 Medroxyprogesterone improved these symptoms in 85% of women. 8 Reducing the dosage of estrogen or stopping hormone replacement therapy in postmenopausal women alleviates mastalgia.
Diuretics have been tried for the treatment of nodularity and breast tenderness, but there is very little evidence to support their use. 21 s PALPABLE BREAST LUMP Most breast lumps are benign. 22, 23 Nevertheless, they are a considerable source of anxiety to patients.
Key points in the history are the onset, duration, and progress of the lump, any past history of breast problems, and any surgical procedures of the breast. Any risk factors for breast cancer should be noted, eg, age, family history of breast cancer, personal history of breast cancer, or biopsy showing atypical hyperplasia, but most women with breast cancer have no identifiable risk factors.
A careful examination of the breast and the axillary and supraclavicular lymph nodes is essential. A benign mass is usually threedimensional, mobile, and smooth, has regular borders, and is solid or cystic in consistency. A malignant mass is usually firm in consistency, has irregular borders, and may be fixed to the underlying skin or soft tissue. There may also be skin changes or nipple retraction.
Follow-up of breast lumps
Women older than 35 years with a discrete breast mass (solid or cystic) should undergo bilateral diagnostic mammography to look for evidence of malignancy. 9 In contrast, breast cancer is rare in women younger than 35 years, and the diagnostic yield of a mammogram is low due to dense breast tissue. 22 Therefore, in young women a mammogram should be obtained only if the mass is suspicious for malignancy on clinical examination or if there is a strong family history of breast cancer.
If the mass is cystic on examination, the next step is needle aspiration. If the aspirate is nonbloody and the mass disappears completely, all the patient needs is a follow-up clinical breast examination after 4 to 6 weeks. If the fluid is bloody or if there is a residual mass on clinical breast examination, the aspirate should be sent to the laboratory for cytologic study and the patient should be referred to a surgeon. Recurrent cyst formation is another Some centers advocate a combination of physical examination, fine needle aspiration cytology, and mammography or ultrasonography. 25 If all three are positive for cancer, the diagnosis is confirmed on open biopsy in more than 99% of cases; when all three are benign, cancer is found in fewer than 0.5% of cases. 26 If it is unclear on clinical examination whether the mass is solid or cystic, needle aspiration can be performed in the office as a first step. Alternatively, the patient can be directly referred to a breast specialist.
If the clinical breast examination and mammogram are normal but the patient says she can feel a lump, a follow-up clinical breast examination should be scheduled after 3 months. 5 Diffuse nodularity without a discrete lump should be followed clinically at midcycle after one or two menstrual cycles. 9 s NIPPLE DISCHARGE In a prospective study, Urban 27 found that 11.8% of women with nonlactational nipple discharge had carcinoma of the breast; the number was 32% in patients older than 60 years who had spontaneous bloody nipple discharge.
Physiologic nipple discharge
Physiologic nipple discharge is usually seen only with nipple manipulation. It is usually bilateral and involves multiple ducts. The discharge may be milky, yellow, green, brown, or black, and is generally nonbloody and nonwatery. A spontaneous nonmalignant bloody discharge is seen occasionally in the third trimester of pregnancy. It usually resolves spontaneously and needs a full workup only if it persists after delivery.
Common causes of physiologic nipple discharge are extensive nipple manipulation, vigorous aerobic exercise, stress, pregnancy, and Montgomery tubercles in adolescents. 9, 28 Follow-up. If the discharge is determined to be physiologic, the patient should be reassured, and surgical referral is not needed. A follow-up visit should be scheduled to ensure that no new symptoms develop and that the problem resolves.
Persistent nonlactational galactorrhea
Galactorrhea is a spontaneous, milky, nonlactational discharge, usually bilateral and from multiple ducts, resulting from elevated prolactin levels. If it persists, it suggests an underlying medical condition and should be evaluated, especially if there are certain concurrent symptoms. For example, amenorrhea and visual symptoms should raise the possibility of a pituitary tumor. Other causes of galactorrhea include chest wall trauma, cirrhosis, spinal cord lesions, hypothyroidism, anovulatory syndromes, and drugs such as estrogens, tricyclic antidepressants, and cimetidine.
Follow-up. A medical evaluation should be started, including the serum prolactin level, the thyroid-stimulating hormone level, magnetic resonance imaging (MRI) of the brain to evaluate the pituitary gland, and a funduscopic examination to look for papilledema.
Medications that cause galactorrhea should be discontinued. Patients with galactorrhea can be treated with bromocriptine. 29 A patient on bromocriptine should be initially followed at intervals of 3 months. The drug may be discontinued in 3 months if the symptoms subside. Bromocriptine can restore fertility in patients with amenorrhea; therefore, patients should be warned about the possibility of getting pregnant.
Pathologic nipple discharge
Pathologic nipple discharge is usually unilateral, confined to one duct, spontaneous, commonly bloody or watery, purulent, cloudy, serous, milky, and sometimes associated with a mass.
Persistent galactorrhea, amenorrhea, and visual symptoms raise the possibility of a pituitary tumor
Intraductal papilloma is the most common cause of pathologic nipple discharge, followed by mammary duct ectasia. 27 Other causes include cancer and mastitis.
Follow-up. A pathologic discharge warrants immediate surgical referral and bilateral mammograms (specifying the patient's symptoms so that optimal views are obtained). 22 If the discharge is not bloody but shows signs of a pathologic process, it should be tested for occult blood. The role of nipple fluid cytology and galactography is controversial and will depend on local practice style. 27 Most patients with pathologic discharge will need terminal duct excision, which is diagnostic and, in the case of benign causes such as papillomatosis and duct ectasia, therapeutic.
s BREAST INFECTIONS AND INFLAMMATION
Mastitis or inflammation of the breast can be broadly classified as lactational or nonlactational. 30 The diagnosis of lactational mastitis is generally straightforward, but it is important for the general internist to be able to differentiate nonlactational breast infections from inflammatory breast cancer.
Lactational mastitis
Lactational mastitis occurs when breast ducts are blocked with engorged milk, and bacteria enter from cracks in the nipple skin. A wedgeshaped abscess in the peripheral part of the breast tissue subsequently develops. There may be associated breast engorgement and axillary lymphadenopathy.
Treatment includes symptom-relieving measures such as warm compresses and acetaminophen for pain and fever. Encourage the patient to continue breast-feeding with the unaffected breast, and once letdown occurs in the affected breast, feed with the affected breast until it is completely empty. A 10-day course of a penicillinase-resistant antibiotic such as dicloxacillin or nafcillin should be started. A localized abscess will require incision and drainage, and the material should be sent for culture.
Nonlactational mastitis
Nonlactational mastitis is characterized by periareolar abscesses, typically resulting from duct ectasia, in which lactiferous ducts become obstructed with cellular debris and lipid-laden material. This is followed by retrograde entry of bacteria from the skin, producing periductal inflammation and abscess formation.
This disease has a chronic recurrent course. The patient presents with noncyclic mastalgia, nipple discharge or retraction, periareolar abscess, subareolar mass, or cellulitis of overlying skin. Spontaneous peripheral abscesses in nonlactating women are generally associated with conditions such as diabetes and immunosuppressive diseases such as human immunodeficiency virus infection.
Follow-up. Subareolar and periareolar nonlactational abscesses require surgical referral, as these need prolonged antibiotic treatment and duct excision. Nonlactational peripheral duct abscesses should be drained, and the underlying cause (eg, diabetes) should also be treated. Patients with sporadic, infectious, nonlactational mastitis and Mondor disease should undergo mammography. 7, 15 Mondor disease is an uncommon selflimiting condition of the breast characterized by superficial thrombophlebitis. 31 Clinical features include sudden-onset breast pain and visible, palpable, tender, cord-like, branching cutaneous grooves. These findings usually resolve spontaneously over 6 weeks to 6 months. The treatment is mainly symptomatic, with analgesics and warm compresses.
Inflammatory breast cancer causes pain, redness, and induration of the skin, usually affecting the dependent portion of the breast. The progression of symptoms is very rapid, and within 1 month the breast may have the peau d'orange appearance (dimpled, like the skin of an orange). Any patient in whom presumed mastitis does not resolve completely after 1 month of treatment with antibiotics warrants surgical referral to rule out inflammatory breast cancer. The further workup of patients with category 3-"probably benign"-lesions is less clear. We believe they should have a followup clinical breast examination and a followup mammogram at 6 months, as suggested by Sickles 32 in an analysis of a series of 7,484 category 3 cases. In this series, 36 cancers developed in 3 years of follow-up; of these, 6 were detected by mammography at 6 months and 2 more were detected by palpation between 6 months and 1 year. Although mammographic screening at 6 months would therefore appear to have a low yield, 4 (80%) of the 5 aggressive tumors that occurred in this series were detected before 1 year.
On the other hand, the utility of the 6-month follow-up mammogram for category 3 findings has been debated. Alternatives have been suggested, such as only following up women with nonpalpable, noncalcified solitary nodules or using fine needle aspiration cytology. 33 The general internist faced with this predicament should refer the patient to a breast specialist, especially if the patient is not satisfied with mammography as the only follow-up.
s THE FUTURE: NEW TUMOR MARKERS AND IMAGING
Many new diagnostic tests such as tumor markers and imaging techniques are currently being studied for the screening of breast cancer, its diagnosis, and its differentiation from benign breast disease. Ductal lavage. For women at high risk of breast cancer (eg, with either a strong family history, personal history of breast cancer, or personal history of atypical proliferative breast lesions), potential risk-stratifying strategies include ductal lavage or ductoscopy to obtain specimens for cytologic study. 34 Tumor markers. Expression of P53 in immunohistochemical staining of fine needle aspiration specimens of breast lesions may help identify the subgroup of patients with benign breast lesions who are at a higher risk of malignant transformation. 35 Women with benign proliferative breast lesions who demonstrate overexpression of HER-2/neu amplification may be at a substantially higher risk of developing subsequent breast cancer. 36 MRI. A number of studies found MRI to have a high sensitivity (88% to 100%) in diagnosing breast cancer. However, the specificity is variable (37% to 97%). 37 The role of MRI in differentiating benign from malignant lesions needs to be better defined, as MRI could potentially decrease the number of invasive biopsies that need to be performed. In a study by Daniel et al, 38 dynamic spiral MRI of the breast could not differentiate ductal carcinoma in situ from other benign lesions.
Nuclear imaging. Technetium-99m methoxyisobutylisonitrile (MIBI) scintimammography may have a role in the diagnosis of palpable breast lesions that cannot be clearly defined by conventional mammography. In theory, this imaging study might decrease the number of biopsies. 39 The workup of 'probably benign' mammogram lesions is not clear
